Alpha Cognition Inc (ACOG)

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K/A - Current report: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company...

Form 8-K - Current report

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form 8-K - Current report

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company...